Clopidogrel mkt exceeds KRW 500 bil for the first time
By Kim, Jin-Gu | translator Kim, Jung-Ju
24.02.16 12:08:53
가나다라
0
Outpatient prescription sales rise from KRW 493.5 billion to KRW 532.7 billion...8% increase in 1 year
Sales growth of original 'Plavix' slows down... 2% YoY increase.
Prescription of generic drugs grew by over 10%...Samjin, Dong-A, Daewoong, Chong Kun Dang show strong sales
▲Photo of Plavix, produced by Handok and marketed by Sanofi in Korea
The antiplatelet market for clopidogrel has grown to exceed KRW 500 billion in Korea. Although 25 years have passed since the original drug, Sanofi's Plavix, was released in Korea, its market is still showing growth.Last year, the growth of generic products stood out in the market. The combined prescription sales of generic products increased by more than 10% year-on-year. Major generic products from Samjin Pharmaceutical, Daewoong Pharmaceutical, Chong Kin Dang, Jeil Pharmaceutical, and Yuhan Corp also showed prescription growth of over 10%.
Clopidogrel prescription market exceeds KRW 500 billion…still shows growth 25 years after original’s launch
According to th
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)